mk-2060
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 29, 2019 (NCT03873038)
Timeline
Indications
Mechanism of action
- Coagulation factor XIINHIBITOR
F11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06582602 | Phase 1 | Oct 15, 2024 | Merck |
| NCT05769595 | Phase 1 | Jun 14, 2023 | Merck |
| NCT06843993 | Phase 1 | Mar 1, 2023 | Merck |
| NCT05656040 | Phase 1 | Jan 10, 2023 | Merck |
| NCT05335005 | Phase 1 | May 30, 2022 | Merck |
| NCT05027074 | Phase 2 | Sep 17, 2021 | Merck |
| NCT03873038 | Phase 1 | Apr 29, 2019 | Merck |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 7 | 7 | 2 | 2019 |
1 organizations
Page 1 / 1